SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop…
Month: March 2023
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop…
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of…
Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of…
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support…
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support…
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Cidara Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
TScan Therapeutics Announces CEO Transition
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as…
TScan Therapeutics Announces CEO Transition
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as…